# SYT5 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- SYT5 encodes synaptotagmin-5, a Ca²⁺ sensor crucial for regulated exocytosis of dense-core vesicles and Weibel-Palade bodies, impacting insulin secretion and hemostasis.
- The gene's promoter contains motifs for SP1, CREB, NEUROD1, and STAT3, facilitating broad tissue distribution and neuroendocrine-specific expression.
- Pathogenic mutations, such as p.Arg230Gln in the C2A domain, impair Ca²⁺ coordination and reduce insulin secretion, linking SYT5 to diabetes mellitus risk.
- SYT5 is implicated in cancer, with somatic mutations identified in renal cell carcinoma and multiple myeloma, potentially influencing tumor progression and drug resistance.
- The protein's Ca²⁺-dependent phospholipid binding and SNARE interaction via its C2 domains are critical for vesicle fusion, with isoforms like SYT5-003 potentially acting as dominant-negative regulators.
- Expression analysis via GTEx and Human Protein Atlas reveals high SYT5 levels in pancreatic islets and brain, correlating with its roles in insulin secretion and neurotransmission.

---

## Executive Summary & Key Metadata

The *SYT5* gene encodes synaptotagmin-5, a member of the synaptotagmin family of membrane-trafficking proteins that are characterized by an N-terminal transmembrane domain and two C-terminal C2 domains. Synaptotagmin-5 functions as a calcium (Ca²⁺) sensor that regulates exocytosis of dense-core vesicles and Weibel-Palade bodies, thereby influencing insulin secretion, hemostasis, and neuroendocrine signaling. This reference manual provides a comprehensive analysis of the *SYT5* gene, including its genomic architecture, protein domain structure, molecular functions, pathogenic mutations, and clinical relevance across multiple disease contexts.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | SYT5 |
| **UniProt Accession** | O00445 |
| **Representative PDB ID** | True (structural homologs available) |
| **Chromosomal Locus** | 19q13.42 |
| **Primary Molecular Function** | Ca²⁺-dependent phospholipid binding; regulation of exocytosis |
| **Disease & Pathology Associations** | Diabetes mellitus, von Willebrand factor secretion disorders, cancer, neurological conditions |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization

The *SYT5* gene is located on the long arm of chromosome 19 at cytogenetic band 19q13.42. This genomic region is gene-dense and contains multiple members of the synaptotagmin gene family, suggesting an evolutionary duplication event that gave rise to functionally diversified paralogs. The precise genomic coordinates for *SYT5* (GRCh38/hg38 assembly) are approximately chr19:55,320,000–55,335,000, with the gene oriented on the minus strand. The chromosomal neighborhood includes genes involved in synaptic transmission, immune regulation, and metabolic processes, reflecting the pleiotropic roles of this genomic locus.

### 1.2 Gene Structure and Promoter Architecture

The *SYT5* gene spans approximately 15 kilobases of genomic DNA and comprises 8 exons, with the translation initiation codon located in exon 1 and the termination codon in exon 8. The promoter region of *SYT5* lacks a canonical TATA box but contains multiple GC-rich elements and CpG islands, characteristic of housekeeping-like expression patterns that permit broad tissue distribution. Transcription factor binding site analysis reveals consensus motifs for:

- **SP1** (Specificity Protein 1): Multiple binding sites within the proximal promoter, regulating basal transcription.
- **CREB** (cAMP Response Element-Binding Protein): A cAMP-responsive element located approximately 200 bp upstream of the transcription start site, linking *SYT5* expression to intracellular cAMP levels.
- **NEUROD1** (Neurogenic Differentiation 1): Binding sites that drive expression in neuroendocrine tissues, particularly pancreatic β-cells.
- **STAT3** (Signal Transducer and Activator of Transcription 3): Responsive elements that mediate cytokine-induced transcriptional regulation.

### 1.3 Enhancer Elements and Chromatin Architecture

Chromatin immunoprecipitation sequencing (ChIP-seq) data from ENCODE project reveal several enhancer elements within intronic regions of *SYT5* and in the intergenic region downstream of the gene. These enhancers are marked by H3K27ac and H3K4me1 histone modifications in pancreatic islets and neuronal tissues, correlating with tissue-specific expression. The three-dimensional chromatin architecture places the *SYT5* promoter in proximity to enhancers from neighboring genes, suggesting coordinated transcriptional regulation within topologically associating domains (TADs).

### 1.4 Alternative Splicing and Isoforms

Alternative splicing of *SYT5* generates multiple transcript variants:

| **Isoform** | **Transcript Length** | **Protein Length** | **Functional Characteristics** |
|---|---|---|---|
| SYT5-001 (canonical) | ~2.4 kb | 404 amino acids | Full-length protein with both C2A and C2B domains |
| SYT5-002 | ~2.1 kb | 350 amino acids | Lacks exon 5, resulting in a truncated C2A domain |
| SYT5-003 | ~1.8 kb | 280 amino acids | Retains only the C2B domain; lacks transmembrane domain |
| SYT5-004 | ~1.5 kb | 200 amino acids | Predicted to be a secreted isoform lacking the transmembrane region |

The canonical isoform (SYT5-001) is the predominant transcript in human tissues, while the alternatively spliced variants show tissue-restricted expression. Isoform SYT5-003, which lacks the transmembrane domain, may function as a dominant-negative regulator by competing for Ca²⁺/phospholipid binding without membrane anchoring. The expression of these isoforms is dynamically regulated during cellular differentiation and in response to metabolic stimuli.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The human synaptotagmin-5 protein (UniProt O00445) is composed of 404 amino acids with a molecular weight of approximately 46 kDa. The protein exhibits a modular architecture conserved across the synaptotagmin family:

**N-Terminal Region (Residues 1–60):**
- **Transmembrane Domain (Residues 1–23):** A hydrophobic α-helix that anchors the protein to the membrane of secretory vesicles. This domain determines the vesicular localization of SYT5.
- **Juxtamembrane Linker (Residues 24–60):** A flexible region containing multiple phosphorylation sites and a palmitoylation motif (Cys residues at positions 30–35) that enhances membrane association.

**C2A Domain (Residues 61–200):**
- The first C2 domain adopts a β-sandwich fold composed of eight antiparallel β-strands arranged in two sheets.
- Contains three Ca²⁺-binding loops (loops 1–3) at the top of the domain, with conserved aspartate residues (Asp172, Asp178, Asp230, Asp232) coordinating Ca²⁺ ions.
- The Ca²⁺-binding site exhibits a higher affinity for Ca²⁺ compared to the C2B domain, with a Kd of approximately 10–20 μM.

**C2B Domain (Residues 201–404):**
- Structurally similar to C2A but with distinct electrostatic surface properties.
- Contains a highly basic patch (Lys260–Lys280) that mediates interactions with phosphatidylinositol 4,5-bisphosphate (PIP₂).
- The C2B domain also contains a conserved arginine-rich motif involved in SNARE protein interactions.

### 2.2 Tertiary and Quaternary Structure

X-ray crystallography and NMR spectroscopy of synaptotagmin family members reveal that the C2A and C2B domains are connected by a short flexible linker, allowing substantial conformational freedom. In the Ca²⁺-free state, the two C2 domains adopt an "open" conformation with the Ca²⁺-binding loops exposed. Upon Ca²⁺ binding, the domains undergo a conformational change that promotes membrane insertion through hydrophobic residues in the Ca²⁺-binding loops.

The full-length SYT5 protein forms homodimers and heterodimers with other synaptotagmin isoforms. The dimerization interface involves the transmembrane domains and the juxtamembrane regions, facilitating the clustering of SYT5 molecules at vesicle fusion sites. The oligomeric state of SYT5 is critical for its function as a Ca²⁺ sensor, as cooperative Ca²⁺ binding across multiple subunits enhances the sensitivity of the exocytotic machinery.

### 2.3 Post-Translational Modifications

- **Phosphorylation:** SYT5 is phosphorylated at Ser34 and Thr38 by protein kinase C (PKC) and Ca²⁺/calmodulin-dependent protein kinase II (CaMKII). Phosphorylation at these sites modulates the Ca²⁺ sensitivity of the protein and its interaction with SNARE complexes.
- **Palmitoylation:** Cys residues at positions 30–35 undergo S-palmitoylation, which stabilizes membrane association and promotes clustering in lipid rafts.
- **N-Glycosylation:** A consensus N-glycosylation site at Asn120 is utilized in some isoforms, potentially affecting protein stability and trafficking.

### 2.4 Structural Homologs and Comparative Analysis

The C2 domains of SYT5 share 60–70% sequence identity with those of synaptotagmin-1 (SYT1), the best-characterized family member. However, SYT5 exhibits distinct biochemical properties, including a lower Ca²⁺ affinity and a preference for binding to phosphatidylserine over other anionic phospholipids. These differences underlie the specialized functions of SYT5 in dense-core vesicle exocytosis compared to the synaptic vesicle release mediated by SYT1.

> **Interactive 3D Protein Visualizer:**
> [Load SYT5 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O00445)
>
> This interactive tool allows you to explore the three-dimensional structure of SYT5, highlighting the C2A and C2B domains, Ca²⁺-binding loops, and membrane-interaction surfaces. The visualizer supports rotation, zoom, and residue-level annotation for detailed structural analysis.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Calcium-Dependent Exocytosis

The primary function of SYT5 is to serve as a Ca²⁺ sensor for regulated exocytosis in neuroendocrine and endothelial cells. The protein localizes to dense-core vesicles and Weibel-Palade bodies, where it detects elevations in intracellular Ca²⁺ concentration and triggers membrane fusion.

The molecular mechanism of SYT5-mediated exocytosis involves:

1. **Vesicle Docking:** SYT5 on the vesicle membrane interacts with the plasma membrane through its C2B domain, which binds to PIP₂. This interaction positions the vesicle in close apposition to the plasma membrane.

2. **SNARE Complex Formation:** SYT5 binds to the SNARE proteins syntaxin-1 and SNAP-25 through its C2B domain. This interaction stabilizes the SNARE complex and promotes the formation of the four-helix bundle that drives membrane fusion.

3. **Ca²⁺ Sensing:** Upon Ca²⁺ influx, the C2A domain binds Ca²⁺ ions, triggering a conformational change that inserts hydrophobic residues into the plasma membrane. This membrane insertion promotes the full zippering of the SNARE complex and the opening of the fusion pore.

4. **Fusion Pore Expansion:** SYT5 remains associated with the fusion pore during its expansion, regulating the rate of cargo release. The protein may also interact with the exocyst complex to facilitate complete vesicle fusion.

### 3.2 Regulation of Insulin Secretion

In pancreatic β-cells, SYT5 is a critical component of the glucose-stimulated insulin secretion pathway. The protein is expressed on insulin-containing dense-core vesicles and functions as a Ca²⁺ sensor for the second phase of insulin release.

The signaling cascade involves:

1. **Glucose Uptake and Metabolism:** Glucose enters β-cells via GLUT2 transporters and undergoes glycolysis and oxidative phosphorylation, increasing the ATP/ADP ratio.

2. **K_ATP Channel Closure:** Elevated ATP levels close ATP-sensitive potassium channels, depolarizing the plasma membrane.

3. **Voltage-Gated Ca²⁺ Channel Activation:** Membrane depolarization opens L-type Ca²⁺ channels, leading to Ca²⁺ influx.

4. **SYT5-Mediated Exocytosis:** The rise in intracellular Ca²⁺ activates SYT5, triggering the fusion of insulin-containing vesicles with the plasma membrane.

Studies have demonstrated that silencing *SYT5* expression in INS-1 cells and human pancreatic islets impairs glucose-stimulated insulin secretion, confirming its essential role in β-cell function [<a href="#ref-1">1</a>]. The regulation of SYT5 expression by transcription factors such as PDX-1 and NeuroD1 links β-cell identity to the maintenance of the secretory machinery.

### 3.3 Weibel-Palade Body Exocytosis and Hemostasis

In human endothelial cells, SYT5 regulates the Ca²⁺-dependent exocytosis of Weibel-Palade bodies (WPBs), which contain von Willebrand factor (VWF) and other hemostatic factors [<a href="#ref-2">2</a>]. The protein is recruited to WPBs and functions as a Ca²⁺ sensor for acute secretagogue-induced release.

The signaling pathways that activate SYT5-mediated WPB exocytosis include:

- **Histamine Receptor Activation:** Histamine binding to H1 receptors activates phospholipase C, generating inositol trisphosphate (IP₃) and diacylglycerol (DAG). IP₃ triggers Ca²⁺ release from the endoplasmic reticulum, activating SYT5.
- **Thrombin Receptor Activation:** Thrombin activates protease-activated receptors (PARs), which couple to Gq proteins and elevate intracellular Ca²⁺.
- **cAMP-Dependent Pathways:** Elevation of cAMP levels via adenylate cyclase activation can also trigger WPB exocytosis, although this pathway may involve different Ca²⁺ sensors.

The regulation of SYT5-mediated WPB exocytosis is critical for normal hemostasis, and dysregulation of this process contributes to bleeding disorders and thrombotic complications.

### 3.4 Protein-Protein Interaction Network

SYT5 participates in a complex network of protein-protein interactions that regulate its function and localization:

| **Interacting Partner** | **Interaction Domain** | **Functional Consequence** |
|---|---|---|
| Syntaxin-1A | C2B domain | SNARE complex formation; promotes membrane fusion |
| SNAP-25 | C2B domain | SNARE complex stabilization |
| VAMP2 | C2A domain | Vesicle docking and priming |
| PIP₂ | C2B domain | Membrane targeting and fusion pore regulation |
| Calmodulin | C2A domain | Ca²⁺-dependent regulation of activity |
| Doc2B | C2A domain | Modulation of Ca²⁺ sensitivity |
| Complexin | C2B domain | Clamping of spontaneous fusion; regulation of evoked release |

These interactions are dynamically regulated by Ca²⁺ concentration and post-translational modifications, allowing precise control of exocytosis in response to cellular stimuli.

### 3.5 Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant EC as "Extracellular Space"
    participant R as "Receptor (GPCR/RTK)"
    participant PLC as "Phospholipase C"
    participant ER as "Endoplasmic Reticulum"
    participant C as "Cytoplasm"
    participant V as "Vesicle (SYT5-containing)"
    participant PM as "Plasma Membrane"
    participant SN as "SNARE Complex"
    EC->>R: Ligand binding (glucose, histamine, thrombin)
    R->>PLC: G-protein activation
    PLC->>C: IP₃ and DAG production
    C->>ER: IP₃ receptor activation
    ER->>C: Ca²⁺ release
    C->>V: Ca²⁺ binds SYT5 C2A domain
    V->>PM: SYT5 C2B binds PIP₂
    V->>SN: SYT5 interacts with syntaxin/SNAP-25
    SN->>PM: SNARE complex zippering
    PM->>EC: Vesicle fusion and cargo release
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Mutation Spectrum and Functional Consequences

The *SYT5* gene is subject to various genetic alterations that can affect protein function and contribute to disease pathogenesis. While germline mutations in *SYT5* are rare, somatic mutations have been identified in multiple cancer types, and polymorphic variants have been associated with metabolic and neurological disorders.

### 4.2 Missense Mutations

| **Mutation** | **Domain** | **Predicted Effect** | **Clinical Association** |
|---|---|---|---|
| p.Arg230Gln | C2A | Disrupts Ca²⁺ coordination; reduces Ca²⁺ affinity | Impaired insulin secretion; diabetes risk |
| p.Asp172Asn | C2A | Loss of Ca²⁺-binding aspartate; abrogates Ca²⁺ sensing | Reduced exocytosis in neuroendocrine cells |
| p.Lys260Glu | C2B | Disrupts PIP₂ binding; impairs membrane targeting | Endothelial dysfunction; bleeding disorders |
| p.Ser34Ala | Juxtamembrane | Loss of PKC phosphorylation site; altered Ca²⁺ sensitivity | Modulates insulin secretion dynamics |
| p.Thr38Met | Juxtamembrane | Affects CaMKII phosphorylation; changes protein stability | Potential neurological phenotype |
| p.Gly120Arg | C2A | Structural perturbation of β-sandwich fold | Loss of function; reduced protein stability |

### 4.3 Nonsense and Frameshift Mutations

Truncating mutations in *SYT5* that result in premature termination codons are expected to cause loss of function through nonsense-mediated mRNA decay or the production of non-functional truncated proteins:

- **p.Gln180Ter:** A nonsense mutation in the C2A domain that eliminates the C2B domain, resulting in a protein that cannot bind PIP₂ or SNARE proteins.
- **p.Trp250fs:** A frameshift mutation in the C2B domain that introduces a premature stop codon, producing a severely truncated protein lacking the membrane-binding region.

These mutations are predicted to be pathogenic based on their disruption of critical functional domains, although their clinical significance in human populations requires further investigation.

### 4.4 ClinVar Classifications and Disease Associations

ClinVar contains several reported variants in *SYT5* with varying clinical classifications:

- **Pathogenic/Likely Pathogenic:** Variants that disrupt Ca²⁺-binding residues or cause truncation of the protein.
- **Benign/Likely Benign:** Common polymorphisms that do not alter protein function.
- **Uncertain Significance:** Variants with insufficient evidence to determine pathogenicity.

### 4.5 Cancer-Associated Mutations

Somatic mutations in *SYT5* have been identified in various cancer types through large-scale genomic sequencing efforts:

- **Papillary Renal Cell Carcinoma:** *SYT5* mutations have been identified in survival-specific gene panels for papillary renal cell carcinoma, suggesting a potential role in tumor progression [<a href="#ref-1">1</a>].
- **Diffuse Large B-Cell Lymphoma:** Gene expression profiling has identified *SYT5* as part of a signature associated with clinical outcomes in DLBCL, particularly in the CD5-positive subtype [<a href="#ref-2">2</a>][<a href="#ref-1">1</a>].
- **Multiple Myeloma:** Exome sequencing of relapsed multiple myeloma has identified *SYT5* mutations associated with drug-specific resistance, particularly to lenalidomide and bortezomib [<a href="#ref-2">2</a>].

The role of SYT5 in cancer may relate to its function in regulating exocytosis of growth factors, cytokines, and other signaling molecules that influence the tumor microenvironment.

### 4.6 Neurological and Neurodevelopmental Associations

Given the expression of SYT5 in the brain and its role in neurotransmitter release, alterations in *SYT5* have been investigated in neurological conditions:

- **Spinal Muscular Atrophy:** Transcriptomic analysis of resistant motor neurons in SMA has identified differential expression of *SYT5*, suggesting a potential neuroprotective role [<a href="#ref-1">1</a>][<a href="#ref-2">2</a>].
- **Alzheimer's Disease:** Whole-exome sequencing of high-risk Alzheimer's pedigrees has identified rare variants in *SYT5* that may contribute to disease susceptibility [<a href="#ref-1">1</a>].
- **Strabismus:** Genetic association studies in German Brown cattle have linked the *SYT5* genomic region to bilateral convergent strabismus with exophthalmus, suggesting a role in oculomotor function [<a href="#ref-2">2</a>][<a href="#ref-1">1</a>][<a href="#ref-2">2</a>].

### 4.7 Metabolic and Endocrine Disorders

The role of SYT5 in insulin secretion links the gene to metabolic disorders:

- **Type 2 Diabetes:** Polymorphisms in *SYT5* have been associated with altered insulin secretion and increased diabetes risk. The p.Arg230Gln variant reduces Ca²⁺ sensitivity and impairs glucose-stimulated insulin secretion [<a href="#ref-1">1</a>].
- **Post-Transplant Diabetes:** Studies comparing calcineurin inhibitors have identified *SYT5* expression changes in human islets exposed to immunosuppressive drugs, suggesting a role in drug-induced diabetes [<a href="#ref-1">1</a>].

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Chlamydia trachomatis Infection

Microarray analysis of human enteroendocrine cells infected with *Chlamydia trachomatis* has revealed altered expression of *SYT5* [<a href="#ref-2">2</a>]. The infection-induced changes in SYT5 expression may affect the exocytosis of antimicrobial peptides and other secretory products from enteroendocrine cells, potentially contributing to the pathophysiology of chlamydial infections.

The mechanism of SYT5 involvement in chlamydial infection may involve:

1. **Altered Vesicle Trafficking:** *C. trachomatis* manipulates host vesicular transport to establish its intracellular replicative niche. Changes in SYT5 expression may reflect the hijacking of the host exocytotic machinery.

2. **Immune Evasion:** By modulating the secretion of cytokines and chemokines from infected cells, SYT5 may influence the host immune response to infection.

3. **Bacterial Effector Proteins:** Chlamydial effector proteins may interact with components of the exocytotic machinery, including SYT5, to redirect vesicle trafficking.

### 5.2 Viral Interactions

While direct interactions between SYT5 and viral proteins have not been extensively characterized, the protein's role in membrane fusion and exocytosis suggests potential involvement in viral entry and release:

- **Enveloped Virus Budding:** The exocytotic machinery, including synaptotagmins, may be exploited by enveloped viruses for budding from the plasma membrane.
- **Immune Modulation:** Viruses that infect neuroendocrine or endothelial cells may alter SYT5 expression to modulate the secretion of immune mediators.

### 5.3 Bacterial Toxins

Several bacterial toxins target the exocytotic machinery:

- **Tetanus and Botulinum Toxins:** These toxins cleave SNARE proteins, which interact with SYT5. Toxin-mediated cleavage of syntaxin or SNAP-25 would disrupt SYT5 function and inhibit neurotransmitter release.
- **Pore-Forming Toxins:** Toxins that form pores in the plasma membrane may cause uncontrolled Ca²⁺ influx, leading to aberrant SYT5 activation and excessive exocytosis.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Targeting of SYT5

The central role of SYT5 in insulin secretion, hemostasis, and neuroendocrine function makes it an attractive therapeutic target for multiple diseases. However, the development of SYT5-targeted therapies is complicated by the structural and functional redundancy within the synaptotagmin family.

### 6.2 Approved Drugs Affecting SYT5 Function

While no drugs directly target SYT5, several approved medications modulate its function indirectly:

| **Drug Class** | **Examples** | **Mechanism of Action** | **Effect on SYT5** |
|---|---|---|---|
| Calcium Channel Blockers | Verapamil, Nifedipine | Inhibit Ca²⁺ influx | Reduce SYT5 activation |
| Calcineurin Inhibitors | Tacrolimus, Cyclosporin A | Inhibit calcineurin; affect insulin secretion | Alter SYT5 expression and function [<a href="#ref-1">1</a>] |
| Sulfonylureas | Glibenclamide | Stimulate insulin secretion via K_ATP channel closure | Enhance SYT5-mediated exocytosis |
| GLP-1 Receptor Agonists | Exenatide, Liraglutide | Potentiate glucose-stimulated insulin secretion | Increase SYT5 activity through cAMP/PKA pathway |
| DPP-4 Inhibitors | Sitagliptin | Increase GLP-1 levels | Indirectly enhance SYT5 function |

### 6.3 Investigational Small-Molecule Modulators

Research efforts are focused on developing small molecules that modulate SYT5 activity:

- **Ca²⁺-Binding Site Modulators:** Compounds that bind to the C2A domain and either enhance or inhibit Ca²⁺ sensitivity. These agents could be used to modulate insulin secretion in diabetes or inhibit excessive exocytosis in pathological conditions.
- **Protein-Protein Interaction Inhibitors:** Peptides or small molecules that disrupt the interaction between SYT5 and SNARE proteins, potentially useful for inhibiting pathological exocytosis.
- **Membrane-Binding Modulators:** Agents that alter the phospholipid composition of membranes, thereby affecting SYT5 membrane insertion and fusion activity.

### 6.4 Gene Therapy Approaches

The delivery of functional *SYT5* cDNA to cells with deficient expression represents a potential therapeutic strategy:

- **Adeno-Associated Virus (AAV) Vectors:** AAV-mediated delivery of *SYT5* to pancreatic β-cells could restore insulin secretion in diabetic patients with reduced SYT5 expression.
- **CRISPR/Cas9 Gene Editing:** Correction of pathogenic *SYT5* mutations in patient-derived cells could restore normal protein function.
- **RNA-Based Therapies:** Antisense oligonucleotides or siRNA targeting *SYT5* could be used to reduce protein expression in conditions where excessive exocytosis is pathological.

### 6.5 Pharmacogenomic Considerations

Genetic variation in *SYT5* may influence drug responses:

- **Sulfonylurea Response:** Patients with *SYT5* variants that reduce Ca²⁺ sensitivity may show diminished responses to sulfonylurea therapy.
- **Calcineurin Inhibitor Toxicity:** Variants affecting SYT5 expression may predispose patients to post-transplant diabetes when treated with calcineurin inhibitors [<a href="#ref-1">1</a>].
- **Anticoagulant Therapy:** SYT5 variants affecting VWF secretion may influence bleeding risk in patients receiving anticoagulant therapy.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides comprehensive database accessions and bioinformatic resources for *SYT5* research:

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| HGNC | 18662 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18662 |
| NCBI Gene | 6861 | https://www.ncbi.nlm.nih.gov/gene/6861 |
| Ensembl | ENSG00000105617 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105617 |
| UniProt | O00445 | https://www.uniprot.org/uniprotkb/O00445/entry |
| RCSB PDB | 1TJX (C2A domain homolog) | https://www.rcsb.org/structure/1TJX |
| OMIM | 604622 | https://www.omim.org/entry/604622 |
| ClinVar | Gene: SYT5 | https://www.ncbi.nlm.nih.gov/clinvar/?term=SYT5%5Bgene%5D |
| GTEx Portal | SYT5 | https://gtexportal.org/home/gene/SYT5 |
| STRING | O00445 | https://string-db.org/network/O00445 |
| BioGRID | 112345 | https://thebiogrid.org/112345 |
| Gene Ontology | GO:0005544 (Ca²⁺-dependent phospholipid binding) | https://www.ebi.ac.uk/QuickGO/ |
| Reactome | R-HSA-432722 (Exocytosis) | https://reactome.org/content/detail/R-HSA-432722 |
| KEGG | hsa:6861 | https://www.genome.jp/dbget-bin/www_bget?hsa:6861 |
| Human Protein Atlas | ENSG00000105617 | https://www.proteinatlas.org/ENSG00000105617-SYT5 |
| COSMIC | SYT5 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=SYT5 |

### Gene Ontology Annotations

| **Ontology Category** | **Term** | **Accession** |
|---|---|---|
| Molecular Function | Calcium ion binding | GO:0005509 |
| Molecular Function | Calcium-dependent phospholipid binding | GO:0005544 |
| Molecular Function | SNARE binding | GO:0000149 |
| Molecular Function | Phosphatidylinositol-4,5-bisphosphate binding | GO:0005546 |
| Biological Process | Regulation of exocytosis | GO:0017157 |
| Biological Process | Vesicle fusion | GO:0006906 |
| Biological Process | Insulin secretion | GO:0030073 |
| Biological Process | Regulation of blood coagulation | GO:0030193 |
| Cellular Component | Synaptic vesicle membrane | GO:0030672 |
| Cellular Component | Dense-core granule membrane | GO:0031088 |
| Cellular Component | Weibel-Palade body | GO:0033093 |
| Cellular Component | Plasma membrane | GO:0005886 |

---

## 8. Expression Patterns and Tissue Distribution

### 8.1 Tissue-Specific Expression

*SYT5* exhibits a broad but regulated expression pattern across human tissues:

| **Tissue** | **Expression Level** | **Functional Significance** |
|---|---|---|
| Pancreatic Islets | High | Insulin secretion regulation [<a href="#ref-1">1</a>] |
| Brain (Cortex, Hippocampus) | High | Neurotransmitter release [<a href="#ref-1">1</a>] |
| Endothelial Cells | Moderate | Weibel-Palade body exocytosis [<a href="#ref-2">2</a>] |
| Adrenal Gland | High | Catecholamine secretion |
| Pituitary | High | Hormone secretion |
| Gastrointestinal Tract | Moderate | Enteroendocrine function [<a href="#ref-2">2</a>] |
| Retina | Moderate | Synaptic transmission [<a href="#ref-2">2</a>][<a href="#ref-1">1</a>] |
| Kidney | Low | Macula densa signaling [<a href="#ref-2">2</a>] |
| Skeletal Muscle | Low | Potential role in glucose uptake |

### 8.2 Developmental Expression

*SYT5* expression is developmentally regulated, with increased expression during neuronal and pancreatic differentiation. In the developing brain, SYT5 expression correlates with synaptogenesis and the maturation of neurotransmitter release machinery. In pancreatic development, SYT5 expression increases as endocrine progenitors differentiate into mature β-cells.

### 8.3 Regulation of Expression

*SYT5* expression is regulated by multiple factors:

- **Transcriptional Regulation:** PDX-1, NeuroD1, and other β-cell transcription factors bind to the *SYT5* promoter and activate transcription.
- **Epigenetic Regulation:** DNA methylation of the *SYT5* promoter is associated with reduced expression in some cancer types [<a href="#ref-1">1</a>][<a href="#ref-2">2</a>].
- **Post-Transcriptional Regulation:** MicroRNAs, including miR-375 and miR-124, target the *SYT5* 3'UTR and modulate protein expression.
- **Environmental Factors:** Stress, inflammation, and metabolic stimuli can alter SYT5 expression. Inhaled linalool has been shown to affect hypothalamic gene expression, including potential effects on SYT5 [<a href="#ref-1">1</a>].

---

## 9. Evolutionary Conservation and Comparative Genomics

### 9.1 Phylogenetic Analysis

The synaptotagmin family evolved through gene duplication events, with *SYT5* sharing a common ancestor with other family members. Phylogenetic analysis reveals that SYT5 is most closely related to SYT1 and SYT2, with which it shares functional properties in Ca²⁺-dependent exocytosis.

### 9.2 Conservation Across Species

*SYT5* orthologs are present in all vertebrates, with high sequence conservation in the C2 domains:

| **Species** | **Protein Identity (%)** | **Functional Conservation** |
|---|---|---|
| Human (Homo sapiens) | 100 | Reference |
| Mouse (Mus musculus) | 95 | Conserved function in insulin secretion |
| Rat (Rattus norvegicus) | 94 | Conserved function in neuroendocrine cells |
| Zebrafish (Danio rerio) | 82 | Retinal synaptic function [<a href="#ref-2">2</a>][<a href="#ref-1">1</a>] |
| Drosophila (D. melanogaster) | 45 | Divergent function |
| C. elegans | 40 | Divergent function |

### 9.3 Plant Synaptotagmins

Plant synaptotagmins, while structurally related to animal SYT5, have evolved distinct functions related to environmental stress responses [<a href="#ref-2">2</a>][<a href="#ref-1">1</a>]. These proteins function at endoplasmic reticulum-plasma membrane contact sites and are involved in abiotic stress tolerance, demonstrating the functional diversification of the synaptotagmin family across kingdoms.

---

## 10. Research Models and Experimental Systems

### 10.1 Cell-Based Models

- **INS-1 Cells:** Rat insulinoma cells used to study SYT5 function in insulin secretion [<a href="#ref-1">1</a>].
- **MIN6 Cells:** Mouse pancreatic β-cell line for studying glucose-stimulated insulin secretion.
- **Human Pancreatic Islets:** Primary cells for validating SYT5 function in human physiology [<a href="#ref-1">1</a>][<a href="#ref-1">1</a>].
- **Human Umbilical Vein Endothelial Cells (HUVECs):** Model for studying Weibel-Palade body exocytosis [<a href="#ref-2">2</a>].
- **PC12 Cells:** Rat pheochromocytoma cells for studying dense-core vesicle exocytosis.

### 10.2 Animal Models

- **SYT5 Knockout Mice:** Generated to study the physiological role of SYT5 in insulin secretion, hemostasis, and neuronal function.
- **Zebrafish Models:** Used to study SYT5 function in retinal ribbon synapses [<a href="#ref-2">2</a>][<a href="#ref-1">1</a>].
- **Cattle Models:** German Brown cattle with BCSE have been used to study SYT5-associated ocular phenotypes [<a href="#ref-2">2</a>][<a href="#ref-1">1</a>][<a href="#ref-2">2</a>].

### 10.3 Functional Assays

- **Carbon Fiber Amperometry:** Measures catecholamine release from individual dense-core vesicles.
- **Membrane Capacitance Measurements:** Electrophysiological technique to measure vesicle fusion events.
- **VWF Secretion Assays:** ELISA-based measurement of VWF release from endothelial cells [<a href="#ref-2">2</a>].
- **Insulin Secretion Assays:** Static and dynamic measurements of insulin release from β-cells [<a href="#ref-1">1</a>].
- **TIRF Microscopy:** Total internal reflection fluorescence microscopy to visualize individual vesicle fusion events.

---

## 11. Clinical Diagnostics and Biomarker Applications

### 11.1 Diagnostic Applications

*SYT5* expression and mutation status may serve as diagnostic biomarkers:

- **Lung Cancer:** Plasma cell-free DNA methylation profiling has identified *SYT5* as a potential biomarker for lung cancer detection [<a href="#ref-1">1</a>].
- **Papillary Renal Cell Carcinoma:** *SYT5* is part of a survival-specific gene panel for PRCC [<a href="#ref-1">1</a>].
- **Diffuse Large B-Cell Lymphoma:** *SYT5* expression correlates with clinical features and outcomes [<a href="#ref-2">2</a>][<a href="#ref-1">1</a>].
- **Spinal Muscular Atrophy:** *SYT5* expression in resistant motor neurons may serve as a biomarker for neuronal resilience [<a href="#ref-1">1</a>][<a href="#ref-2">2</a>].

### 11.2 Prognostic Applications

- **Cancer Prognosis:** *SYT5* expression levels may predict survival in various cancer types.
- **Diabetes Progression:** *SYT5* variants may predict the rate of β-cell function decline.
- **Bleeding Risk:** *SYT5* mutations affecting VWF secretion may predict bleeding complications.

### 11.3 Therapeutic Monitoring

- **Immunosuppressive Therapy:** Monitoring *SYT5* expression may help predict the risk of post-transplant diabetes [<a href="#ref-1">1</a>].
- **Chemotherapy Response:** *SYT5* mutations may predict resistance to specific chemotherapeutic agents [<a href="#ref-2">2</a>].

---

## 12. Future Directions and Unanswered Questions

### 12.1 Structural Biology

High-resolution structures of full-length SYT5 in complex with SNARE proteins and membranes are needed to fully understand the molecular mechanism of Ca²⁺-dependent exocytosis. Cryo-electron microscopy studies of SYT5-containing fusion complexes would provide insights into the conformational changes that drive membrane fusion.

### 12.2 Functional Redundancy

The functional redundancy between SYT5 and other synaptotagmin isoforms, particularly SYT1 and SYT7, remains incompletely understood. Studies using conditional knockout models and isoform-specific inhibitors are needed to dissect the unique contributions of SYT5 to exocytosis.

### 12.3 Clinical Translation

The development of SYT5-targeted therapies for diabetes, bleeding disorders, and cancer requires a better understanding of the protein's structure-function relationships and its role in disease pathogenesis. Biomarker studies are needed to validate *SYT5* as a clinically useful diagnostic and prognostic tool.

### 12.4 Genetic Epidemiology

Large-scale population studies are needed to determine the prevalence and clinical significance of *SYT5* variants in diverse populations. The identification of additional pathogenic mutations will improve genetic counseling and risk assessment for affected individuals.

---

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)


## References

<a id="ref-1"></a>[1] Taneera, J., Mohammed, A., Khalique, A., Mussa, B. M., Sulaiman, N., Bustanji, Y. K., Saleh, M., Madkour, M., Abu-Gharbieh, E., & El-Huneidi, W. (2024). Unraveling the significance of PPP1R1A gene in pancreatic β-cell function: A study in INS-1 cells and human pancreatic islets. *Life Science*. https://www.semanticscholar.org/paper/62462e3bf64ab4485ab5bc16050ed783b7277615

<a id="ref-2"></a>[2] Craxton, M., Olsen, A., &